Neuroscience

 

25 Results were found on Technologies

2-2013-728

Microelecronic scaffold for tissue engineering

Read More >

Leading Researchers:
10-2007-105

BBS Ab -A novel target for Alzheimer's and ALS immunotherapy

THE TECHNOLOGYBBS is a monoclonal antibody that binds specifically and blocks beta-secretase (BACE1) cleavage site on its substrate, APP. BBS inhibits Ab production, a hall-mark of AD and other neurodegenerative diseases such as ALS.The... Read More >

Leading Researchers:
2-2016-978

Neuromuscular junction Multi-electrode arrays

Neuromuscular Junction - multi electrode arrays (NMJ-MEA) – a novel drug high-throughput synapse activity functional screening device Finding efficient treatments to neurodegenerative diseases and spinal cord injury has not yet been... Read More >

Leading Researchers:
5-2015-883

High resolution deep tissue imaging of turbid media

TechnologyImaging through turbid media such as occluding body fluids (e.g. blood, urine, CSF) is restricted due to strong scattering. In applications such as intravascular optical imaging applications clearing of the imaging path (the lumen) are... Read More >

Leading Researchers:
10-2019-1237

A new type of GSK-3 Small Molecule Inhibitors for Treating Multiple Pathologies

Additional information will be provided upon request Read More >

Leading Researchers:
2-2011-158

Mouse model of progressive multiple sclerosis

The Technology Multiple sclerosis (MS) is an autoimmune disease of the central nervous system characterized by damage to the neuronal myelin sheath, which results in different levels of muscle paralysis that can lead to neuronal death. In... Read More >

Leading Researchers:
10-2014-850

Ultra-low doses of tetrahydrocannabinol (THC) for cognitive deficits

Ultra-low doses of THC for the treatment of cognitive deficits Prof. Sarne has published several studies on neuroprotection induced by ultra-low doses of THC against cognitive damage that results from various insults, including... Read More >

10-2013-549

Novel specific disease-modifying PERK activator for Huntington’s disease

There is no efficient therapy at present for Huntington’s disease (HD) nor for any other neurodegenerative disease, including Alzheimer’s and Parkinson’s diseases. No disease-modifying approaches exist. Gene therapy-based clinical trials have... Read More >

Leading Researchers:
8-2021-1598

Mapping Transverse Relaxation in Preclinical MRI Scanners

UNMET NEEDAccurate quantitative magnetic resonance imaging (qMRI) is gradually becoming indispensable in clinical diagnostics and research. It’s application on preclinical MRI scanners, however, is hampered by the use of strong imaging gradients,... Read More >

Leading Researchers:
10-2011-259

Immunotherapy for Stroke and Cognition in a Cerebral Amyloid Angiopathy Animal Model

Cerebrovascular dysfunction is a fundamental part of the pathology of several neurodegenerative diseases and rated as one of the most prominent cause for dementia. Cerebral amyloid angiopathy (CAA) results in intra-parenchymal and subarachnoid... Read More >